Safety first: pIOL is effective for myopic astigmatism

Article

Implantation of the Artiflex toric iris-fixated phakic IOL is effective, predictable and safe for the correction of myopic astigmatism.

Implantation of the Artiflex toric iris-fixated phakic IOL is effective, predictable and safe for the correction of myopic astigmatism, claims a study in the Journal of Cataract and Refractive Surgery.

Dr Gonzalo Muñoz et al., Refractive Surgery Department, Marqués de Sotelo Ophthalmic Clinic, Barcelona, Spain, conducted a cohort study on 42 eyes of 25 patients age 21 to 39 years.

Refraction, uncorrected (UDVA) and corrected (CDVA) distance visual acuities, complications, pIOL misalignment, and endothelial cell count (ECC) were evaluated 12 months postoperatively. Vector analysis was used to calculate indices of success and misalignment.

Mean spherical equivalent was reduced from −8.85 D ± 2.71 SD to −0.37 ± 0.46 D, with 66.7% of the eyes within ±0.50 D. Mean cylinder power reduced from−2.90 D to −0.39 D. A UDVA of 0.5 or better was achieved in all eyes, along with a CDVA of 0.8 or better.

Mean clinical pIOL misalignment was 2.6 ± 1.8 degrees and one eye required surgical repositioning of the pIOL. Mean ECC reduction was 9.3% ± 1.8%, with iris pigment precipitates observed in 16.7% of eyes. Vector analysis demonstrated excellent mean indices of success for overall, spherical and astigmatic corrections.

Related Videos
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Colman Cawe, director of fundraising and communications, Orbis UK
Greg Kunst, CEO of Aurion Biotech
Related Content
© 2023 MJH Life Sciences

All rights reserved.